Jayme L Dahlin1, Michael A Walters. 1. Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Abstract
It is increasingly clear that academic high-throughput screening (HTS) and virtual HTS triage suffers from a lack of scientists trained in the art and science of early drug discovery chemistry. Many recent publications report the discovery of compounds by screening that are most likely artifacts or promiscuous bioactive compounds, and these results are not placed into the context of previous studies. For HTS to be most successful, it is our contention that there must exist an early partnership between biologists and medicinal chemists. Their combined skill sets are necessary to design robust assays and efficient workflows that will weed out assay artifacts, false positives, promiscuous bioactive compounds and intractable screening hits, efforts that ultimately give projects a better chance at identifying truly useful chemical matter. Expertise in medicinal chemistry, cheminformatics and purification sciences (analytical chemistry) can enhance the post-HTS triage process by quickly removing these problematic chemotypes from consideration, while simultaneously prioritizing the more promising chemical matter for follow-up testing. It is only when biologists and chemists collaborate effectively that HTS can manifest its full promise.
It is increasingly clear that academic high-throughput screening (HTS) and virtual HTS triage suffers from a lack of scientists trained in the art and science of early drug discovery chemistry. Many recent publications report the discovery of compounds by screening that are most likely artifacts or promiscuous bioactive con class="Gene">mpounds, and these results are not placed into the context of previous studies. For HTS to be most successful, it is our contention that there must exist an early partnership between biologists and medicinal chemists. Their combined skill sets are necessary to design robust assays and efficient workflows that will weed out assay artifacts, false positives, promiscuous bioactive compounds and intractable screening hits, efforts that ultimately give projects a better chance at identifying truly useful chemical matter. Expertise in medicinal chemistry, cheminformatics and purification sciences (analytical chemistry) can enhance the post-HTS triage process by quickly removing these problematic chemotypes from consideration, while simultaneously prioritizing the more promising chemical matter for follow-up testing. It is only when biologists and chemists collaborate effectively that HTS can manifest its full promise.
Authors: Jessica A Kilgore; Xinlin Du; Lisa Melito; Shuguang Wei; Changguang Wang; Hang Gyeong Chin; Bruce Posner; Sriharsa Pradhan; Joseph M Ready; Noelle S Williams Journal: J Biol Chem Date: 2013-05-13 Impact factor: 5.157
Authors: Karina M Soares; Nicole Blackmon; Tong Ying Shun; Sunita N Shinde; Harold K Takyi; Peter Wipf; John S Lazo; Paul A Johnston Journal: Assay Drug Dev Technol Date: 2010-04 Impact factor: 1.738
Authors: Lewis R Vidler; Panagis Filippakopoulos; Oleg Fedorov; Sarah Picaud; Sarah Martin; Michael Tomsett; Hannah Woodward; Nathan Brown; Stefan Knapp; Swen Hoelder Journal: J Med Chem Date: 2013-10-03 Impact factor: 7.446
Authors: Jayme L Dahlin; J Willem M Nissink; Subhashree Francis; Jessica M Strasser; Kristen John; Zhiguo Zhang; Michael A Walters Journal: Bioorg Med Chem Lett Date: 2015-08-10 Impact factor: 2.823
Authors: Christos A Nicolaou; Christine Humblet; Hong Hu; Eva M Martin; Frank C Dorsey; Thomas M Castle; Keith Ian Burton; Haitao Hu; Jorg Hendle; Michael J Hickey; Joel Duerksen; Jibo Wang; Jon A Erickson Journal: ACS Med Chem Lett Date: 2019-02-04 Impact factor: 4.345
Authors: Christopher K McLaughlin; Da Duan; Ahil N Ganesh; Hayarpi Torosyan; Brian K Shoichet; Molly S Shoichet Journal: ACS Chem Biol Date: 2016-01-15 Impact factor: 5.100